Department of Laboratory, Guangzhou General Hospital of Guangzhou Military Command, No.111, Liuhua Rd, Yuexiu District, Guangzhou 510010, China.
Technol Cancer Res Treat. 2011 Jun;10(3):287-94. doi: 10.7785/tcrt.2012.500205.
This study aimed to investigate the diagnostic values of GP73 protein in patients' serum with primary hepatic carcinoma (PHC). Also GP73 mRNA expression level in peripheral blood mononuclear cells (PBMCs) and liver tissue between health controls and PHC patients was interrogated. Finally the role of combined detection of serum GP73 and alpha-fetoprotein (AFP) in high-risk population screening was evaluate, in an attempt to justify the new, sensitive, specific and rapid measure for the diagnosis and detection of PHC. Serum proteins of GP73 and AFP were examined in 73 patients with PHC, 13 patients with hepatic cirrhosis, 32 patients with hepatitis and 62 healthy subjects using enzyme-linked immunosorbent assay (ELISA). The relative expression levels of GP73 mRNA in PBMCs and liver tissues were examined by using SYBR Green quantitative reverse transcription polymerase chain reaction (RT-PCR) assay, calculated with the comparison of Cq value. In contrast to patients with cirrhosis and hepatitis, or healthy subjects, PHC patients had their serum GP73 and AFP significantly elevated (P < 0.05) while their PBMCs GP73 mRNA was not significantly different from those with cirrhosis and hepatitis, or healthy subjects (P > 0.05). The expression level of GP73 mRNA was significantly higher in PHC liver tissue than in normal liver tissue. The sensitivity for serum GP73 and AFP in PHC was 68.5% and 28.8%, respectively while that for the combined detection was up to 74%, justifying that the combined detection could prevent the false negative diagnosis by AFP alone and significantly improve the detection rate. As a new diagnostic biomarker of PHC, GP73 protein in serum was highly sensitive and specific. GP73 mRNA in PHC liver tissue specimens instead of whole blood could be used for the diagnosis of PHC as a tumor biomarker, whose detection was highly invasive, risky and afflicting otherwise. The combined detection of GP73 and AFP in serum effectively improved the diagnosis of PHC, in addition to the screening in high-risk population.
本研究旨在探讨 GP73 蛋白在原发性肝癌(PHC)患者血清中的诊断价值。还检测了健康对照组和 PHC 患者外周血单个核细胞(PBMC)和肝组织中 GP73mRNA 的表达水平。最后,评估了联合检测血清 GP73 和甲胎蛋白(AFP)在高危人群筛查中的作用,旨在为 PHC 的诊断和检测提供新的、敏感、特异和快速的方法。采用酶联免疫吸附试验(ELISA)检测 73 例 PHC 患者、13 例肝硬化患者、32 例肝炎患者和 62 例健康对照者血清 GP73 和 AFP 蛋白。采用 SYBR Green 实时定量逆转录聚合酶链反应(RT-PCR)检测 PBMC 和肝组织中 GP73mRNA 的相对表达水平,通过 Cq 值比较计算。与肝硬化和肝炎患者或健康对照者相比,PHC 患者的血清 GP73 和 AFP 显著升高(P<0.05),而其 PBMCs GP73mRNA 与肝硬化和肝炎患者或健康对照者无显著差异(P>0.05)。GP73mRNA 在 PHC 肝组织中的表达水平明显高于正常肝组织。血清 GP73 和 AFP 对 PHC 的敏感性分别为 68.5%和 28.8%,而联合检测的敏感性高达 74%,证明联合检测可以防止 AFP 单独检测的假阴性诊断,显著提高检测率。作为 PHC 的一种新的诊断生物标志物,血清 GP73 蛋白具有较高的敏感性和特异性。PHC 肝组织标本中的 GP73mRNA 可作为肿瘤标志物用于 PHC 的诊断,而检测则具有较高的侵袭性、风险性和不适性。血清 GP73 和 AFP 的联合检测可有效提高 PHC 的诊断率,同时还可用于高危人群的筛查。